Remicure Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 17-12-2024
- Paid Up Capital ₹ 1.00 M
as on 17-12-2024
- Company Age 8 Year, 5 Months
- Last Filing with ROC 31 Mar 2024
- Revenue -58.60%
(FY 2022)
- Profit -171.62%
(FY 2022)
- Ebitda -172.54%
(FY 2022)
- Net Worth -26.15%
(FY 2022)
- Total Assets -17.67%
(FY 2022)
About Remicure Life Sciences
The Company is engaged in the Business Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 1.00 M, as per Ministry of Corporate Affairs (MCA) records.
Roshan Pulla, Pulla Rahul, Sairishi Pulla, and Four other members serve as directors at the Company.
- CIN/LLPIN
U74999TG2016PTC110734
- Company No.
110734
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
06 Jul 2016
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Remicure Life Sciences?
Board Members(7)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sairishi Pulla  | Additional Director | 06-Jul-2020 | Current |
| Abhishek Manepalli | Additional Director | 06-Jul-2020 | Current |
| Roshan Pulla | Director | 06-Jul-2016 | Current |
| Pulla Rahul | Additional Director | 15-Dec-2017 | Current |
| Venugopal Pulla | Additional Director | 06-Jul-2020 | Current |
| Pappala Naveen | Additional Director | 06-Jul-2020 | Current |
Financial Performance of Remicure Life Sciences.
Remicure Life Sciences Private Limited, for the financial year ended 2022, experienced significant reduction in revenue, with a 58.6% decrease. The company also saw a substantial fall in profitability, with a 171.62% decrease in profit. The company's net worth observed a substantial decline by a decrease of 26.15%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Remicure Life Sciences?
Unlock access to Remicure Life Sciences's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Remicure Life Sciences?
Unlock and access historical data on people associated with Remicure Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Remicure Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Remicure Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
